Your session is about to expire
← Back to Search
Other
TNP-2092 for Prosthetic Joint Infections
Phase 1
Waitlist Available
Research Sponsored by TenNor Therapeutics Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male or females, 18 years of age or older
Capable of giving signed informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day2, day7, day14
Awards & highlights
Study Summary
This trial will study how TNP-2092 moves into different tissues in people having either a hip or knee replacement surgery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day2, day7, day14
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day2, day7, day14
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Concentration of TNP-2092 in bone
Concentration of TNP-2092 in synovial fluid
Secondary outcome measures
Plasma PK of a single IV dose of TNP-2092
Rate of adverse event with TNP-2092
Side effects data
From 2020 Phase 2 trial • 120 Patients • NCT0396449315%
Nausea
9%
Cellulitis
8%
Vomiting
3%
Wound infection
1%
MRSA bacteremia and worsening cellulitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
TNP-2092
Vancomycin
Trial Design
1Treatment groups
Experimental Treatment
Group I: TNP-2092 300mg IVExperimental Treatment1 Intervention
TNP-2092 for injection 100mg/vial, 300mg, BID, 1 dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TNP-2092
2016
Completed Phase 2
~200
Find a Location
Who is running the clinical trial?
TenNor Therapeutics LimitedLead Sponsor
2 Previous Clinical Trials
126 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger